• Overactive bladder/enuresis

Vesicare Generic Name & Formulations

General Description

Solifenacin succinate 5mg, 10mg; tabs.

Pharmacological Class

Muscarinic antagonist.

See Also

How Supplied

Tabs—30, 90; Susp—150mL

Generic Availability


Vesicare Indications


Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vesicare Dosage and Administration


Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: max 5mg once daily.


Not established.

Vesicare Contraindications


For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.

Vesicare Boxed Warnings

Not Applicable

Vesicare Warnings/Precautions


Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.

Vesicare Pharmacokinetics

See Literature

Vesicare Interactions


Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Vesicare Adverse Reactions

Adverse Reactions

Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).

Vesicare Clinical Trials

See Literature

Vesicare Note

Not Applicable

Vesicare Patient Counseling

See Literature